PDCI Market Access | Canada’s Leading Pricing and Reimbursement Consultancy

We help Pharma / Biotech firms:

What's New

15

May

Status Summary Of Innovative Medicine pCPA Negotiations As Of April 30, 2019

02

May

Julia Shen Joins PDCI Market Access!

01

Apr

Helena Koa Joins PDCI Market Access!

22

Mar

PDCI’s New Associate Director, HTA & Health Economics

20

Mar

Kimberly Robinson Joins PDCI Market Access!

19

Mar

Federal Budget 2019 Supporting the Creation of a Canadian Drug Agency

14

Mar

Status Summary of Innovative Medicine pCPA Negotiations as of February 28, 2019

05

Mar

Health Canada and CADTH launch new initiative to provide Early Parallel Scientific Advice

25

Feb

PDCI Research Identifies Opportunities for Reimbursement of Nicotine Replacement Therapies under Employer Health Plans

22

Feb

CADTH Pharmaceutical Reviews Update – Issue 5

15

Feb

Status Summary of Innovative Medicine pCPA Negotiations as of January 31, 2019

11

Feb

Expensive Drugs for Rare Diseases – Provincial Working Group Consultation

07

Feb

CADTH Launches New Parallel Scientific Advice Program

04

Feb

Observations on National Pharmacare from John-Paul Dowson

17

Jan

Status Summary of Negotiations on Brand Name Drugs as of December 31, 2018

08

Jan

All 2019 HDAP Meeting Dates Released

20

Dec

CADTH Releases Pharmaceutical Review Update Issue 4

19

Dec

Holiday Greetings

12

Nov

New INESSS Website Launched

02

Nov

PMPRB October 2018 NEWSletter Released

23

Oct

Register for the Market Access Summit and Save 20% with PDCI

23

Oct

Welcome PDCI New Hires!

01

Oct

REMINDER: PDCI is Sharing Responses to the National Pharmacare Consultation

28

Aug

PDCI Sharing Responses to Pharmacare Consultation

27

Aug

PMPRB 2017 Annual Report Released

30

Jul

ANNOUNCEMENT – Courtney Abunassar

03

Jul

CADTH Publishes New CDR Guidelines & Therapeutic Review Process, providing Framework to Revise CDEC Recommendations

28

Jun

Health Canada, CADTH & INESS Collaborate on Aligned Drug Review Processes

14

Jun

pCPA Releases its Brand Process Guidelines

31

May

CADTH publishes CDR Update – Issue 136

22

May

Join PDCI at the 4th Annual Canadian Institute Pharma Symposium & Save 10% off Registration

11

May

PMPRB’s May 2018 NEWSletter Updates Guideline Reform Timelines

04

May

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

30

Apr

INESSS Updates Submission Guide, Checklists and Template Forms

19

Apr

Standing Committee on Health Publishes Report & Recommendations on National Pharmacare

12

Apr

New pCODR Patient Input Tip Sheet Available

12

Apr

Saskatchewan Budget 2018-19: Province to Provide HIV Medications at No Cost

12

Apr

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

05

Apr

INESSS Releases Additional Information on the Evaluation Process

29

Mar

Reminder: New prices for generics under pCPA/CGPA agreement become effective April 1st, 2018

21

Mar

CADTH Invites Stakeholder Feedback on Proposed Revisions to the pCODR Clinician Engagement Process

09

Mar

CADTH Common Drug Review Releases New Update

08

Mar

PMPRB March 2018 NEWSletter Released

27

Feb

Federal Finance Minister Unveils Advisory Council on the Implementation of National Pharmacare in Budget 2018

23

Feb

Québec Gazette Announces Draft Regulations for Implementation of Fees for INESSS Submissions

14

Feb

CADTH Common Drug Review Releases New Update

08

Feb

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

07

Feb

PMPRB Form 3 (R&D) Due Date Reminder

01

Feb

NEW PDCI Report finds Health Canada significantly overstates benefits & underestimates negative impact of its proposed regulatory amendments

30

Jan

INESSS Releases Additional Information – Requests for Changes of an Administrative Nature

29

Jan

Proposed Amendments To The Patented Medicines Regulations: A Critical Appraisal Of The Cost-Benefit Analysis

22

Jan

PMPRB myth busting (I): The imaginary link between Canadian price controls and R&D expenditures

15

Jan

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

21

Dec

CADTH Common Drug Review Releases New Update

20

Dec

Happy Holidays from PDCI Market Access

14

Dec

TODAY at 1 pm: Government of Canada Officials to Speak on Proposed Regulatory Amendments

11

Dec

PMPRB Releases Guidelines Scoping Paper with Overview of Potential New Framework

07

Dec

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

05

Dec

Health Canada releases proposed PMPRB Price Regulations – The Charge of the Price Brigade

04

Dec

PDCI Webinar: Proposed Amendments to Patented Medicines Regulations – What Patentees Need to Know

04

Dec

Manitoba Health Amends Submission Requirements

01

Dec

Proposed Amendments to Patented Medicines Regulations Announced

29

Nov

INESSS Releases Additional Information on the Continuous Evaluation Process

29

Nov

PDCI’s Top 5 Tips: Block 5

28

Nov

CADTH Common Drug Review Releases New Update

27

Nov

2017 Québec City Healthcare Industry Forum

16

Nov

INESSS Releases Additional Information on the Continuous Evaluation Process

16

Nov

CADTH Common Drug Review Releases New Update

08

Nov

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

08

Nov

INESSS Releases Additional Information on the Continuous Evaluation Process

08

Nov

National Pharmacare: No need for “Repeal & Replace” Canadian edition

03

Nov

INESSS Releases List of Drug Products Currently Being Reviewed Under the Continuous Evaluation Process

01

Nov

PMPRB 2016 Annual Report Released

31

Oct

PDCI is excited to announce another great addition to the PDCI team: John-Paul Dowson, Director, Reimbursement Strategy

30

Oct

PDCI Welcomes Jennifer Haig as Manager, HTA and Health Economics

18

Oct

RAMQ: October 2017 Update for the List of Medications

17

Oct

INESSS Releases Additional Information on the Continuous Evaluation of Drug Products – Mandatory Notification

12

Oct

CADTH Common Drug Review Releases New Update

11

Oct

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

29

Sep

PMPRB Hearing Panel Decision Released: Soliris

29

Sep

INESSS Releases Additional Information on the Continuous Evaluation of Drug Products

29

Sep

CADTH Common Drug Review Releases New Update

12

Sep

Revealing Payments to Physicians: “Health Leaders” going down the wrong road with the PMPRB.

12

Sep

CADTH Common Drug Review Releases New Update

11

Sep

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

08

Sep

Notice to Manufacturers – Medications Under Review for February 2018 List Update

23

Aug

NOW LIVE: PDCI’s Information Sharing Webpage: Responses to Health Canada’s Patented Medicines Regulations Consultation

22

Aug

Sharing Responses on Proposed Amendments to the Patented Medicines Regulations

21

Aug

Notice to Manufacturers – Clarification of List Update Schedule in 2018

14

Aug

CADTH Common Drug Review Releases CDR Update – Issue 126

09

Aug

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

28

Jul

Release of PMPRB Annual Report Delayed (Again) – So much for transparency…

25

Jul

2018 HDAP Meeting Schedule

14

Jul

CADTH Common Drug Review Releases New Update

13

Jul

Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare Program

11

Jul

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

19

Jun

PDCI Market Access Webinar: New INESSS Submission Guidelines and Implementation of Pre-NOC Review Procedure

15

Jun

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

13

Jun

UPDATE: Québec – INESSS Submission Deadline for August 2017

09

Jun

CADTH Common Drug Review Releases New Update

09

Jun

PDCI Market Access Webinar: Information Session for Industry on New INESSS Submission Guidelines and Implementation of Pre-NOC Review Procedure

06

Jun

NEW: INESSS Releases New Submission Guidelines – Implementation of Pre-NOC Review Procedure

30

May

The PMPRB Releases its May 2017 NEWSletter

25

May

PDCI Market Access Webinar: Information Session for Industry on Proposed Amendments to Patented Medicines Regulations

16

May

Patented Medicines Regulations Consultation Open

16

May

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

03

May

PDCI Welcomes Strategic Partner John-Paul Dowson!

02

May

Join PDCI at 3rd Annual Canadian Institute Pharma Symposium

19

Apr

New NPDUIS Report Released – PMPRB Meds Entry Watch

19

Apr

New INESSS Questionnaires Released for Medicines Under Review

13

Apr

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

28

Mar

CADTH’s Updated Guidelines for the Economic Evaluation of Health Technologies – 4th Edition Now Available

17

Mar

New CADTH Processes and March Newsletter

16

Mar

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

15

Mar

CADTH Special Event: New Guidelines for the Economic Evaluation of Health Technologies: Canada

15

Mar

INESSS Manufacturer Appointments

17

Feb

PMPRB Form 3 Reminder

06

Feb

Kaitlyn Proulx appointed Managing Director

06

Dec

Health Canada Releases Guidance Document for Biosimilar Biologic Drug Submissions

02

Dec

PMPRB’s Phase 1 of Rethinking the Guidelines Public Comments Now Available

01

Dec

Alberta Changes Special Authorization Criteria for Coverage of INFLECTRA™ (infliximab)

28

Nov

Ontario Public Drug Programs Funds New Indications for INFLECTRA™ (infliximab)

23

Nov

PMPRB Vice Chair Re-appointed

09

Nov

Private Payer Product Listing Agreements in Canada – Second Joint Industry/Payer Survey Results – NOW AVAILABLE

31

Oct

Registration is Open for CAHR’s 6th Annual National Day

20

Oct

INESSS Manufacturer Appointments

13

Oct

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

11

Oct

Application of Generic Substitution to the Exceptional Access Program (EAP)

04

Oct

Addendum #1 to Ontario Guidelines for Drug Submission and Evaluation to the Ontario Public Drug Programs

28

Sep

Alberta Releases New Amendments to Price Policy

26

Sep

Ontario Releases New Amendments to Regulation 201/96 under the ODBA Regulation and Regulation 935 under the DIDFA Regulation

20

Sep

Ontario Releases Updated Guidelines for Drug Submission and Evaluation 2016

13

Sep

Feedback on Proposed Revisions to Patient Input Template for CDR and pCODR

08

Sep

The pCPA: Negotiations Status Update

26

Aug

Registration is Underway for the CAHR Market Access 201 Course

26

Aug

PDCI Market Access WEBINAR ‒ Possible 2nd Session September 8, 2016 (date tentative)

19

Aug

PMPRB 2015 Annual Report Released

17

Aug

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

12

Aug

PDCI Market Access WEBINAR ‒ Information Session on the PMPRB Guidelines Modernization Discussion Paper

10

Aug

PDCI Market Access WEBINAR ‒ Information Session on the PMPRB Guidelines Modernization Discussion Paper

05

Aug

The PMPRB Releases its July 2016 NEWSletter

29

Jul

SAVE THE DATE

21

Jul

PMPRB 2015 Annual Report

12

Jul

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

04

Jul

PMPRB Guideline Modernization – PDCI to hold Industry Information Sessions in August / September

27

Jun

PMPRB – Discussion Paper Released – Board Down to 2 Board Members as of June 27 – 2015 Annual Report Board Delayed

20

Jun

PDCI Releases NEW Report on pCPA Best Practices, Trends and Outlook

03

Jun

BC PharmaCare Upcoming Modernization of the Reference Drug Program

01

Jun

RAMQ: June 2016 Update for the List of Medications

26

May

CADTH CDR and pCODR Engagement with the pCPA

25

May

Nova Scotia Pharmacare Funds INFLECTRA™ (infliximab)

18

May

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

17

May

CADTH Releases Recommendations Report for Anti-Vascular Endothelial Growth Factor Drugs for Retinal Conditions

03

May

The PMPRB Releases its April 2016 NEWSletter

03

May

Seeking Participation in the 2016 Private Payer PLA Survey

22

Apr

New Drug Review Process Developed by INESSS for Stable Blood Products

19

Apr

The pan-Canadian Pharmaceutical Alliance (pCPA) Releases its April 1st, 2016 Update

11

Apr

The pCPA Releases First Principles for Subsequent Entry Biologics

30

Mar

New Implementation Dates for Revisions to the Procedure for Voluntary Withdrawal and Providing CDR Review Team’s Responses

30

Mar

Minimum Period of 120 Calendar Days for Advance Notification of Anticipated Submissions and Resubmissions for CADTH’s CDR and pCODR Programs

24

Mar

The PMPRB to Implement Next Steps Regarding the Compendium of Policies, Guidelines and Procedures in June 2016

24

Mar

Ontario’s CED Will No Longer Routinely Evaluate CDR- or pCODR-Reviewed Drug Products

15

Mar

Ontario Public Drug Programs Funds INFLECTRA™ (infliximab)

15

Mar

CADTH Call for Patient Input for INFLECTRA™ (Subsequent Entry Biologic)

10

Mar

CADTH Call for Patient Input for Etanercept SEB

10

Mar

Proposal to Amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act to Update Cost-Sharing Arrangements for Non-Low Income Seniors under the Ontario Drug Benefit Program

29

Feb

PDCI Pharmacare Costing Study Report 2016 – Final

26

Feb

Update on Procedures for the CADTH Common Drug Review and pan-Canadian Oncology Drug Review: Mandatory Disclosure of a Submitted Drug Price

23

Feb

pCPA February Update – Federal Drug Plans officially join the pCPA and the full Office team is now in place

17

Feb

Ontario Listing of Inflectra

17

Feb

Alexion pCPA Negotiation

12

Feb

Alberta Health Releases Price Confirmation Tentative Dates

12

Feb

PMPRB NEW Report: Generics360 – Generic Drugs in Canada, 2014

12

Feb

Modifications to the Procedure for Filing a Drug Submission Application for Generic Drugs with INESSS

02

Feb

New Pilot Initiative: Increasing Opportunities for Clinical Input and Feedback in CADTH pan-Canadian Oncology Drug Review Process

20

Jan

C-MAP™ Canadian Drug Benefit Plans Reference Guide 2016 Edition NOW AVAILABLE!

18

Jan

PHARMACARE COSTING IN CANADA: Preliminary Report

21

Dec

PMPRB Releases Strategic Plan 2015-2018

14

Dec

Patented Medicine Prices Review Board Releases 2014 Annual Report

14

Dec

Updates to the Guidelines for the Economic Evaluation of Health Technologies: Canada

14

Dec

Québec Moves to Introduce a Tendering System for Drugs

04

Dec

Ontario Releases Summary of Minister’s Roundtable on Pharmacare

25

Nov

PDCI Strategic Advice Services for Product Listing Agreements

13

Nov

PMPRB wins at Federal Court of Appeal – Maintains jurisdiction over patented generic products

03

Nov

Presentation and Poll Results from PDCI Market Access Product Listing Agreement (PLA) Webinar is Now Available

26

Oct

CADTH: Extending Deadline on Consultation on Procedures for the CADTH Common Drug Review

26

Oct

CAHR National Day: National Approaches to Pharma Policy: International & Canadian Perspectives

20

Oct

PDCI Market Access WEBINAR ‒ Market Access Climate Change: the Evolving Impact of Product Listing Agreements

16

Oct

QUÉBEC: INESSS Upcoming Meetings with Manufacturers – June 2016 “Liste des médicaments”

16

Oct

pCPA October Update – Québec officially joins the pCPA & the pCPA Office is now operational

06

Oct

Expanding the CADTH Drug Review Process to Receive Patient Input Submissions from Individual Patients and Caregivers

30

Sep

Manulife DrugWatch™ & Private Payer Product Listing Agreement (PLA) Series

17

Sep

Private Payer Product Listing Agreement (PLA) Series

09

Sep

Private Payer Product Listing Agreement (PLA) Series

03

Sep

Private Payer Product Listing Agreement (PLA) Series

31

Jul

The PMPRB has released its July 2015 NEWSletter

27

Jul

Ontario Public Drug Programs Division

20

Jul

Exceptional Response to PDCI/H3 Private Payer PLA Survey

24

Jun

Private Payer PLA Survey

23

Jun

Australia’s Pharmaceutical Benefits Advisory Committee Recommends Substitution of Biosimilars

19

Jun

QUEBEC: INESSS Upcoming Meetings with Manufacturers – February 2016 “Liste des médicaments”

12

Jun

QUÉBEC – INESSS Submission Deadlines: 2015-2016

08

Jun

PDCI International Trends Series Part 5

27

May

BC: Updates to BC Drug Review Process and Submission Requirements

27

May

ON: Amendments to Ontario Regulation 201/96

26

May

PDCI International Trends Series Part 4

25

May

Canadian Organization for Rare Disorders (CORD) to release first ever Rare Disease Strategy

19

May

PDCI International Trends Series Part 3

14

May

PDCI International Trends Series Part 2

04

May

PDCI International Trends Series

10

Apr

WIB-Greater Montreal and the Technoparc Montréal Present a Conference on Drug Reimbursement in Quebec

10

Apr

Updates to the Manufacturer Submission Requirements in the Alberta Drug Benefit List (ADBL)

07

Apr

CADTH: Guidelines for Manufacturers on pCODR Application Fees Implemented

30

Mar

Rare Diseases Campaign

25

Mar

The pan-Canadian Oncology Drug Review (pCODR) is moving

25

Mar

PDCI Canadian Drug Claims Database FREE TRIAL now available!

12

Mar

CADTH Revised Category 1 Requirements for Tailored CDR Reviews

05

Mar

Guidelines for Manufacturers on Application Fees for pCODR

02

Mar

‘Successful CDR, pCODR & INESSS Submissions’ Workshop CANCELLED

23

Feb

Pan-Canadian Generics – Centralized Price Confirmation Process

09

Feb

Interview with pCPA on the Guidelines for Negotiations

04

Feb

CADTH Update for Patient Groups — January 2015

04

Feb

PMPRB Update – January 2015 NEWSletter

14

Jan

Drug products undergoing evaluation for the June 2015 “Liste des médicaments”

05

Jan

CDEC Final Recommendation for Inflectra Posted

22

Dec

Happy Holidays from PDCI!

14

Nov

PMPRB Has Released its October 2014 NEWSletter

06

Nov

Proposed Regulation Amendments to Establish a Pricing Framework for Generic Products

03

Nov

PDCI Career Opportunity

03

Nov

Voluntary Compliance Undertaking of Valeant Canada LP to PMPRB

24

Oct

Patented Medicines Prices Review Board (PMPRB) Outreach Sessions

22

Oct

Meetings with Manufacturers for the June 2015 “Liste des médicaments”

16

Oct

IBM “Pan Canadian Drugs Negotiation Report” Now Available

08

Oct

Welcome Anita!

07

Oct

PDCI Pan-Canadian Pharmaceutical Alliance (PCPA) Benchmarking Survey Report – NOW AVAILABLE!

03

Oct

CADTH Updates for Patient Groups

02

Oct

PMPRB: The PMPRB Launches its New Website

02

Oct

QUEBEC: October Update for the “Liste des médicaments”

18

Sep

PMPRB: New enhanced PMPRB website coming soon

16

Sep

PMPRB: 2013 Annual Report Released

16

Sep

CADTH: Revised Guidelines for Manufacturers on Application Fees

18

Aug

15th Anniversary Edition of the C-MAP™ Canadian Drug Benefit Plans Reference Guide

06

Aug

CADTH Direct-Acting Antivirals for Chronic Hepatitis C Genotype 1

05

Aug

PMPRB has released its July 2014 NEWSletter

31

Jul

CADTH: Feedback Requested on Industry Application Fee Guidelines

30

Jul

CADTH: CDR Update – Issue 106

29

Jul

New Brunswick: Rare diseases drug plan established

24

Jul

pCODR: Summary Report from Stakeholder Consultations on Transfer of pCODR to CADTH

09

Jul

PMPRB 2013 Annual Report Delayed

08

Jul

CADTH: CDR Update – Issue 105 – Patient Input

08

Jul

QUEBEC: INESSS to have meetings with manufacturers for February 2015 Liste des médicaments update

27

Jun

PMPRB Federal Court Decision Appealed

16

Jun

QUEBEC: Submission deadlines published

29

May

PMPRB jurisdiction does not extend to Generics (Federal Court Decisions)

27

May

Update on pCODR Procedures and Guidelines Consultation

26

May

CADTH: Common Drug Review (CDR) Update – Issue 104

25

May

Invitation to attend PMPRB Outreach sessions

24

May

Common Drug Review (CDR) introduces new application fee for submissions

23

May

The PMPRB releases the April 2014 issue of its NEWSletter

23

May

Québec: Update to the Liste de médicaments

22

May

CADTH: CDEC to review Drugs for Rare Diseases via “enhanced” CDR process

20

Mar

Subsequent Entry Biologics in Canada: Stakeholders Discuss the Regulatory, Pricing and Reimbursement Landscape.

20

Mar

Executive Briefing Pharmaceutical Pricing and Reimbursement in Canada 2012 Edition

20

Mar

National Pharmacare Cost Impact Study

20

Mar

Generic Drug Prices: A Canada US Comparison

20

Mar

Canada’s Balance of Trade in Pharmaceuticals

20

Mar

Parliamentary Review of Bill C-91: Background Study on Drug Costs and Benefits

18

Feb

Actual CPI in 2013 and implications for PMPRB price compliance

18

Feb

Second phase of generic pricing policy implemented yesterday

18

Feb

Premier Announces New Catastrophic Drug Coverage Program

18

Feb

Generic drug prices drop to 35 per cent of brand

18

Feb

Provincial government invests $2.4 million in health research

18

Feb

INESSS to have meetings with manufacturers for June 2014 Liste des médicaments update

18

Feb

Update to the Liste de médicaments

18

Feb

High-income seniors to pay more for drugs

18

Feb

Price for top 10 generic drugs cut to 20% of brand price

18

Feb

New drugs on formulary expected to save $10 million/year

18

Feb

Province announces it will reimburse 100% of the costs of oral cancer drugs

18

Feb

120 new drugs added to Pharmacare last month

18

Feb

Some seniors’ and children’s prescriptions to cost more

18

Feb

Online processing to help Saskatchewan-based travellers receive six-month supplies of drugs

18

Feb

Province introduces Pharmaceutical Services Act

18

Feb

Drug manufacturer submission deadlines for listing on the AHWDBL have been updated

18

Feb

18% Generic Drug Pricing Policy Effective March 15, 2013

18

Feb

CDR Update — Issue 98

18

Feb

Environmental Scan on Subsequent Entry Biologics released

18

Feb

CADTH to post patient input submissions as of February 1, 2014

18

Feb

Canadian Drug Expert Committee (CDEC) Meeting Schedule

18

Feb

Effective April 1 2014: pCODR is transferring to CADTH

14

Feb

New PDCI Study!

14

Feb

Effective April 1 2014: pCODR is transferring to CADTH

13

Feb

PMPRB

12

Feb

CADTH